This Fusion Animation uses 3D medical animation to detail the Mechanism of Action (MOA) of Aflibercept, a pioneering bispecific fusion protein for retinal diseases like neovascular AMD. We visualize the pathophysiology involving VEGFR-1 and VEGFR-2. The animation demonstrates Aflibercept's superior multi-targeted blockade: it traps all ligands of VEGFR-1 and key ligands of VEGFR-2, providing comprehensive inhibition of vascular leakage and neovascularization. This showcases our expertise in Ophthalmology and Anti-VEGF pharmacology.
Ophthalmology Medical Animations
Eye science at its most stunning. Watch us bring ophthalmology to life in cinematic 3D, supporting education and engagement.

AFLIBERCEPT MOA: BLOCKADE OF VEGF SIGNALLING IN RETINAL DISEASE
This Fusion Animation uses 3D medical animation to detail the Mechanism of Action (MOA) of Aflibercept, a pioneering bispecific fusion protein for retinal diseases like neovascular AMD. We visualize the pathophysiology involving VEGFR-1 and VEGFR-2. The animation demonstrates Aflibercept's superior multi-targeted blockade: it traps all ligands of VEGFR-1 and key ligands of VEGFR-2, providing comprehensive inhibition of vascular leakage and neovascularization. This showcases our expertise in Ophthalmology and Anti-VEGF pharmacology.



Brief: explain the underlying causes of dry eye disease to HCPs.




